Affiliation:
1. Endocrine Unit, Division of Nuclear Medicine, National Cancer Institute, Milano
2. Division of Medical Statistics and Biometry, National Cancer Institute, Milano
3. Institute of Medical Statistics and Biometry, University of Milan, Milano - Italy
Abstract
Urinary androstanediol measurement, often in association with other androgens, is commonly used to support the clinical diagnosis of idiopathic hirsutism. In addition, androgen excess has been shown to be the endocrine abnormality which characterizes patients with breast cancer. We recently developed a method for the measurement of urinary testosterone employing solid-phase extraction and HPLC purification before quantitative measurement by gas chromatography. In the present report we verify the feasibility of the method for the simultaneous measurement of 5α-androstane-3α,17β-diol and 5β-androstane-3α,17β-diol in addition to testosterone in the same urine sample. The mean recovery for the whole procedure was 89.8% for 5α-androstane-3α,17β-diol and 87.8% for 5β-androstane-3α, 17β-diol. The estimates of the coefficients of variation were 4.9% (95% confidence limits: 3.9–6.5%) and 3.9% (95% confidence limits: 3.1–5.2%), respectively. Accuracy was evaluated by standard addition and dilution assays and a linear relationship was found between expected and observed values (r2=0.997 for 5α-androstane-3α,17β-diol and r2=0.999 for 5β-androstane-3α,17β-diol). The method is rapid, effective and suitable for the measurement of testosterone, 5α-androstanediol and 5β-an-drostanediol in the same urine sample.
Subject
Cancer Research,Clinical Biochemistry,Oncology,Pathology and Forensic Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献